DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Sign in and take the values quiz to see how this bill lines up with what you've said.
This bill amends patent law to restrict pharmaceutical manufacturers from asserting excessive numbers of patents in litigation against biosimilar competitors, a practice known as 'product hopping.' The bill limits reference product sponsors to asserting no more than 20 patents total (with at most 10 issued after a specified date) in infringement actions against biosimilar applicants, though courts may increase this limit for good cause. The bill also appropriates $1.8 billion to the Medicare Improvement Fund.
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
Sign in to see how your representatives voted on this bill.